Elicio Therapeutics (ELTX) Revenue (2020 - 2022)

Elicio Therapeutics has reported Revenue for 3 years, with the latest figure at $653000.0 in Q2 2022.

• For the quarter ending Q2 2022, Revenue rose 20.93% year-over-year to $653000.0; the trailing twelve-month figure through Mar 2023 stood at $653000.0 (down 97.73% YoY), and the FY2022 full-year result was $2.3 million, down 91.63% from the prior year.
• Revenue for Q2 2022 stood at $653000.0, down from $1.6 million in the prior quarter.
• The five-year high for Revenue was $25.1 million in Q4 2021, with the low at -$2.2 million in Q4 2020.
• Historically, Revenue has averaged $3.2 million across 3 years, with a median of $729000.0 in 2020.
• The largest YoY upside for Revenue was 1228.14% in 2021 against a maximum downside of 25.93% in 2021.
• Elicio Therapeutics' Revenue stood at -$2.2 million in 2020, then surged by 1228.14% to $25.1 million in 2021, then slumped by 97.4% to $653000.0 in 2022.
• The last three Revenue figures came in at $653000.0 (Q2 2022), $1.6 million (Q1 2022), and $25.1 million (Q4 2021), per Business Quant data.